{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:38:31Z","timestamp":1790800711188,"version":"4.1.0"},"reference-count":120,"publisher":"Society of Nuclear Medicine","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2967\/jnumed.121.263198","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:11:10Z","timestamp":1654085470000},"page":"33S-44S","source":"Crossref","is-referenced-by-count":60,"title":["PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders"],"prefix":"10.2967","volume":"63","author":[{"given":"Solveig","family":"Tiepolt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp M.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Patt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Deuther-Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swen","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2022060616200899000_63.Supplement_1.33S.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-0618(03)00068-1"},{"key":"2022060616200899000_63.Supplement_1.33S.2","doi-asserted-by":"crossref","unstructured":"Fisher SK Wonnacott S . Acetylcholine. In: Brady ST Siegel GJ Albers RW Price DL , eds. Basic Neurochemistry. 8th ed. Academic Press; 2012:258\u2013282.","DOI":"10.1016\/B978-0-12-374947-5.00013-4"},{"key":"2022060616200899000_63.Supplement_1.33S.3","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain."},{"key":"2022060616200899000_63.Supplement_1.33S.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2009.12.048"},{"key":"2022060616200899000_63.Supplement_1.33S.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.7046051"},{"key":"2022060616200899000_63.Supplement_1.33S.6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/115.6.1681"},{"key":"2022060616200899000_63.Supplement_1.33S.7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1212\/WNL.0000000000003633","article-title":"Decreased intestinal acetylcholinesterase in early Parkinson disease: an 11C-donepezil PET study","volume":"88","author":"Fedorova","year":"2017","journal-title":"Neurology."},{"key":"2022060616200899000_63.Supplement_1.33S.8","doi-asserted-by":"crossref","first-page":"105557","DOI":"10.1016\/j.nbd.2021.105557","article-title":"Neuropathological evidence of body-first vs. brain-first Lewy body disease","volume":"161","author":"Borghammer","year":"2021","journal-title":"Neurobiol Dis."},{"key":"2022060616200899000_63.Supplement_1.33S.9","doi-asserted-by":"crossref","unstructured":"Wenzel B Deuther-Conrad W Scheunemann M Brust P . Radioligand development for PET imaging of the vesicular acetylcholine transporter (VAChT) in the brain. In: Dierckx RA Otte A de Vries EF van Waarde A Lammertsma AA , eds. PET and SPECT of Neurobiological Systems. Springer International Publishing; 2021:1061\u20131090.","DOI":"10.1007\/978-3-030-53176-8_32"},{"key":"2022060616200899000_63.Supplement_1.33S.10","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/jm9507486","article-title":"Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol","volume":"39","author":"Jung","year":"1996","journal-title":"J Med Chem."},{"key":"2022060616200899000_63.Supplement_1.33S.11","first-page":"405","article-title":"In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM","volume":"35","author":"Kuhl","year":"1994","journal-title":"J Nucl Med."},{"key":"2022060616200899000_63.Supplement_1.33S.12","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199811)30:3<263::AID-SYN4>3.0.CO;2-9"},{"key":"2022060616200899000_63.Supplement_1.33S.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.02.007"},{"key":"2022060616200899000_63.Supplement_1.33S.14","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/205045"},{"key":"2022060616200899000_63.Supplement_1.33S.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.124792"},{"key":"2022060616200899000_63.Supplement_1.33S.16","doi-asserted-by":"publisher","DOI":"10.1002\/cne.24541"},{"key":"2022060616200899000_63.Supplement_1.33S.17","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.183"},{"key":"2022060616200899000_63.Supplement_1.33S.18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41380-018-0130-5","article-title":"Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV","volume":"24","author":"Nejad-Davarani","year":"2019","journal-title":"Mol Psychiatry."},{"key":"2022060616200899000_63.Supplement_1.33S.19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jnc.14291","article-title":"Kinetic modeling of [18F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain","volume":"144","author":"Jin","year":"2018","journal-title":"J Neurochem."},{"key":"2022060616200899000_63.Supplement_1.33S.20","doi-asserted-by":"crossref","first-page":"174556","DOI":"10.1016\/j.ejphar.2021.174556","article-title":"In vitro characterization of [3H]VAT in cells, animal and human brain tissues for vesicular acetylcholine transporter","volume":"911","author":"Liang","year":"2021","journal-title":"Eur J Pharmacol."},{"key":"2022060616200899000_63.Supplement_1.33S.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400309"},{"key":"2022060616200899000_63.Supplement_1.33S.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1392-5"},{"key":"2022060616200899000_63.Supplement_1.33S.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.176180"},{"key":"2022060616200899000_63.Supplement_1.33S.24","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25430"},{"key":"2022060616200899000_63.Supplement_1.33S.25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.28360","article-title":"Cholinergic denervation patterns across cognitive domains in Parkinson\u2019s disease","volume":"36","author":"van der Zee","year":"2021","journal-title":"Mov Disord."},{"key":"2022060616200899000_63.Supplement_1.33S.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248500"},{"key":"2022060616200899000_63.Supplement_1.33S.27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.parkreldis.2021.09.018","article-title":"Normal cognition in Parkinson\u2019s disease may involve hippocampal cholinergic compensation: an exploratory PET imaging study with [18F]-FEOBV","volume":"91","author":"Legault-Denis","year":"2021","journal-title":"Parkinsonism Relat Disord."},{"key":"2022060616200899000_63.Supplement_1.33S.28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00259-016-3555-6","article-title":"Cholinergic PET imaging in infections and inflammation using 11C-donepezil and 18F-FEOBV","volume":"44","author":"J\u00f8rgensen","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022060616200899000_63.Supplement_1.33S.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.05.023"},{"key":"2022060616200899000_63.Supplement_1.33S.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-0618(00)00110-1"},{"key":"2022060616200899000_63.Supplement_1.33S.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(99)00045-3"},{"key":"2022060616200899000_63.Supplement_1.33S.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1986.tb12960.x"},{"key":"2022060616200899000_63.Supplement_1.33S.33","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.2174\/0929867325666180410105135","article-title":"NAChR \u03b14\u03b22 subtype and their relation with nicotine addiction, cognition, depression and hyperactivity disorder","volume":"26","author":"Laikowski","year":"2019","journal-title":"Curr Med Chem."},{"key":"2022060616200899000_63.Supplement_1.33S.34","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/j.1471-4159.1986.tb13113.x","article-title":"Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer\u2019s disease and the normal","volume":"47","author":"Flynn","year":"1986","journal-title":"J Neurochem."},{"key":"2022060616200899000_63.Supplement_1.33S.35","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(86)90629-4"},{"key":"2022060616200899000_63.Supplement_1.33S.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00064-9"},{"key":"2022060616200899000_63.Supplement_1.33S.37","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)00410-7"},{"key":"2022060616200899000_63.Supplement_1.33S.38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300302"},{"key":"2022060616200899000_63.Supplement_1.33S.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2005.12.012"},{"key":"2022060616200899000_63.Supplement_1.33S.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00295-X"},{"key":"2022060616200899000_63.Supplement_1.33S.41","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90819-X"},{"key":"2022060616200899000_63.Supplement_1.33S.42","doi-asserted-by":"crossref","first-page":"10.1002\/syn.21981","DOI":"10.1002\/syn.21981","article-title":"[18F]nifene test-retest reproducibility in first-in-human imaging of \u03b14\u03b22* nicotinic acetylcholine receptors","volume":"71","author":"Lao","year":"2017","journal-title":"Synapse."},{"key":"2022060616200899000_63.Supplement_1.33S.43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.108001"},{"key":"2022060616200899000_63.Supplement_1.33S.44","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuroimage.2015.05.065","article-title":"First-in-human PET quantification study of cerebral \u03b14\u03b22* nicotinic acetylcholine receptors using the novel specific radioligand (\u2212)-[18F]flubatine","volume":"118","author":"Sabri","year":"2015","journal-title":"Neuroimage."},{"key":"2022060616200899000_63.Supplement_1.33S.45","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/brain\/awy099","article-title":"Cognitive correlates of \u03b14\u03b22 nicotinic acetylcholine receptors in mild Alzheimer\u2019s dementia","volume":"141","author":"Sabri","year":"2018","journal-title":"Brain."},{"key":"2022060616200899000_63.Supplement_1.33S.46","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2967\/jnumed.117.205492","article-title":"18F-XTRA PET for enhanced imaging of the extrathalamic \u03b14\u03b22 nicotinic acetylcholine receptor","volume":"59","author":"Coughlin","year":"2018","journal-title":"J Nucl Med."},{"key":"2022060616200899000_63.Supplement_1.33S.47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00259-020-05029-w","article-title":"(+)-[18F]flubatine as a novel \u03b14\u03b22 nicotinic acetylcholine receptor PET ligand: results of the first-in-human brain imaging application in patients with \u03b2-amyloid PET-confirmed Alzheimer\u2019s disease and healthy controls","volume":"48","author":"Tiepolt","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022060616200899000_63.Supplement_1.33S.48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.050716"},{"key":"2022060616200899000_63.Supplement_1.33S.49","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.907"},{"key":"2022060616200899000_63.Supplement_1.33S.50","doi-asserted-by":"crossref","first-page":"10.1002\/syn.22016","DOI":"10.1002\/syn.22016","article-title":"Evaluation of (\u2212)-[18F]flubatine-specific binding: implications for reference region approaches","volume":"72","author":"Bhatt","year":"2018","journal-title":"Synapse."},{"key":"2022060616200899000_63.Supplement_1.33S.51","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0701-1"},{"key":"2022060616200899000_63.Supplement_1.33S.52","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1644-5"},{"key":"2022060616200899000_63.Supplement_1.33S.53","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt195"},{"key":"2022060616200899000_63.Supplement_1.33S.54","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jagp.2016.11.011","article-title":"Cholinergic receptor binding in Alzheimer disease and healthy aging: assessment in\u00a0vivo with positron emission tomography imaging","volume":"25","author":"Sultzer","year":"2017","journal-title":"Am J Geriatr Psychiatry."},{"key":"2022060616200899000_63.Supplement_1.33S.55","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20688"},{"key":"2022060616200899000_63.Supplement_1.33S.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2008.01.010"},{"key":"2022060616200899000_63.Supplement_1.33S.57","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2009.74"},{"key":"2022060616200899000_63.Supplement_1.33S.58","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.106"},{"key":"2022060616200899000_63.Supplement_1.33S.59","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12259"},{"key":"2022060616200899000_63.Supplement_1.33S.60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fnagi.2014.00213","article-title":"Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson\u2019s disease","volume":"6","author":"Isaias","year":"2014","journal-title":"Front Aging Neurosci."},{"key":"2022060616200899000_63.Supplement_1.33S.61","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X"},{"key":"2022060616200899000_63.Supplement_1.33S.62","doi-asserted-by":"publisher","DOI":"10.1038\/nature01339"},{"key":"2022060616200899000_63.Supplement_1.33S.63","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00846.x"},{"key":"2022060616200899000_63.Supplement_1.33S.64","first-page":"548913","article-title":"Brain imaging of nicotinic receptors in Alzheimer\u2019s disease","volume":"2010","author":"Wu","year":"2010","journal-title":"Int J Alzheimers Dis."},{"key":"2022060616200899000_63.Supplement_1.33S.65","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.46"},{"key":"2022060616200899000_63.Supplement_1.33S.66","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.8.5626"},{"key":"2022060616200899000_63.Supplement_1.33S.67","doi-asserted-by":"publisher","DOI":"10.2174\/1568007023339166"},{"key":"2022060616200899000_63.Supplement_1.33S.68","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.6159-08.2009"},{"key":"2022060616200899000_63.Supplement_1.33S.69","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-009-0240-x"},{"key":"2022060616200899000_63.Supplement_1.33S.70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.9758\/cpn.2011.9.3.111","article-title":"Occupancy of \u03b17 nicotinic acetylcholine receptors in the brain by tropisetron: a positron emission tomography study using 11C-CHIBA-1001 in healthy human subjects","volume":"9","author":"Ishikawa","year":"2011","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"2022060616200899000_63.Supplement_1.33S.71","doi-asserted-by":"crossref","unstructured":"Brust P Deuther-Conrad W Donat C . Preclinical and clinical aspects of nicotinic acetylcholine receptor imaging. In: Dierckx RA Otte A de Vries EF van Waarde A Lammertsma AA , eds. PET and SPECT of Neurobiological Systems. Springer International Publishing; 2021:593\u2013660.","DOI":"10.1007\/978-3-030-53176-8_18"},{"key":"2022060616200899000_63.Supplement_1.33S.72","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2174\/138945012800398955","article-title":"Development of radioligands for the imaging of \u03b17 nicotinic acetylcholine receptors with positron emission tomography","volume":"13","author":"Brust","year":"2012","journal-title":"Curr Drug Targets."},{"key":"2022060616200899000_63.Supplement_1.33S.73","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neuroimage.2017.10.009","article-title":"The distribution of the \u03b17 nicotinic acetylcholine receptor in healthy aging: an in\u00a0vivo positron emission tomography study with [18F]ASEM","volume":"165","author":"Coughlin","year":"2018","journal-title":"Neuroimage."},{"key":"2022060616200899000_63.Supplement_1.33S.74","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1248\/bpb.32.337","article-title":"Central in\u00a0vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT)","volume":"32","author":"Ogawa","year":"2009","journal-title":"Biol Pharm Bull."},{"key":"2022060616200899000_63.Supplement_1.33S.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.11.007"},{"key":"2022060616200899000_63.Supplement_1.33S.76","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3233\/JAD-170591","article-title":"In vivo depiction of \u03b17 nicotinic receptor loss for cognitive decline in Alzheimer\u2019s disease","volume":"61","author":"Nakaizumi","year":"2018","journal-title":"J Alzheimers Dis."},{"key":"2022060616200899000_63.Supplement_1.33S.77","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.230979"},{"key":"2022060616200899000_63.Supplement_1.33S.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.09.011"},{"key":"2022060616200899000_63.Supplement_1.33S.79","doi-asserted-by":"publisher","DOI":"10.2174\/138161206778559678"},{"key":"2022060616200899000_63.Supplement_1.33S.80","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.15135"},{"key":"2022060616200899000_63.Supplement_1.33S.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.11.018"},{"key":"2022060616200899000_63.Supplement_1.33S.82","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1995.64041888.x"},{"key":"2022060616200899000_63.Supplement_1.33S.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2005.07.010"},{"key":"2022060616200899000_63.Supplement_1.33S.84","doi-asserted-by":"crossref","first-page":"fcaa058","DOI":"10.1093\/braincomms\/fcaa058","article-title":"M1 muscarinic acetylcholine receptor dysfunction in moderate Alzheimer\u2019s disease pathology","volume":"2","author":"Yi","year":"2020","journal-title":"Brain Commun."},{"key":"2022060616200899000_63.Supplement_1.33S.85","doi-asserted-by":"crossref","first-page":"105044","DOI":"10.1016\/j.nbd.2020.105044","article-title":"Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats","volume":"144","author":"Brugnoli","year":"2020","journal-title":"Neurobiol Dis."},{"key":"2022060616200899000_63.Supplement_1.33S.86","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0873-16.2016"},{"key":"2022060616200899000_63.Supplement_1.33S.87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1988.tb02497.x"},{"key":"2022060616200899000_63.Supplement_1.33S.88","doi-asserted-by":"publisher","DOI":"10.1126\/science.3992249"},{"key":"2022060616200899000_63.Supplement_1.33S.89","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.tips.2019.10.007","article-title":"Targeting muscarinic acetylcholine receptors for the treatment of psychiatric and neurological disorders","volume":"40","author":"Moran","year":"2019","journal-title":"Trends Pharmacol Sci."},{"key":"2022060616200899000_63.Supplement_1.33S.90","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00702-016-1629-z","article-title":"Muscarinic receptor binding changes in postmortem Parkinson\u2019s disease","volume":"124","author":"McOmish","year":"2017","journal-title":"J Neural Transm."},{"key":"2022060616200899000_63.Supplement_1.33S.91","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ph14060530","article-title":"Update on PET tracer development for muscarinic acetylcholine receptors","volume":"14","author":"Ozenil","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"2022060616200899000_63.Supplement_1.33S.92","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.246967"},{"key":"2022060616200899000_63.Supplement_1.33S.93","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.7.741"},{"key":"2022060616200899000_63.Supplement_1.33S.94","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.nucmedbio.2011.06.003","article-title":"Imaging of the muscarinic acetylcholine neuroreceptor in rats with the M2 selective agonist [18F]FP-TZTP","volume":"39","author":"Ravasi","year":"2012","journal-title":"Nucl Med Biol."},{"key":"2022060616200899000_63.Supplement_1.33S.95","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600530"},{"key":"2022060616200899000_63.Supplement_1.33S.96","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/acs.jmedchem.9b01406","article-title":"Discovery of [11C]MK-6884: a positron emission tomography (PET) imaging agent for the study of M4 muscarinic receptor positive allosteric modulators (PAMs) in neurodegenerative diseases","volume":"63","author":"Tong","year":"2020","journal-title":"J Med Chem."},{"key":"2022060616200899000_63.Supplement_1.33S.97","doi-asserted-by":"crossref","first-page":"eabg3684","DOI":"10.1126\/scitranslmed.abg3684","article-title":"The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer\u2019s disease","volume":"14","author":"Li","year":"2022","journal-title":"Sci Transl Med."},{"key":"2022060616200899000_63.Supplement_1.33S.98","doi-asserted-by":"crossref","first-page":"111354","DOI":"10.1016\/j.pscychresns.2021.111354","article-title":"PET imaging of brain muscarinic receptors with 18F-fluorobenzyl-dexetimide: a first in human study","volume":"316","author":"Rowe","year":"2021","journal-title":"Psychiatry Res Neuroimaging."},{"key":"2022060616200899000_63.Supplement_1.33S.99","doi-asserted-by":"crossref","first-page":"fcaa098","DOI":"10.1093\/braincomms\/fcaa098","article-title":"Cholinergic muscarinic M1\/M4 receptor networks in dementia with Lewy bodies","volume":"2","author":"Colloby","year":"2020","journal-title":"Brain Commun."},{"key":"2022060616200899000_63.Supplement_1.33S.100","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1007\/s00415-015-7827-z","article-title":"Regional covariance of muscarinic acetylcholine receptors in Alzheimer\u2019s disease using (R, R) [123I]-QNB SPECT","volume":"262","author":"Colloby","year":"2015","journal-title":"J Neurol."},{"key":"2022060616200899000_63.Supplement_1.33S.101","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1471-4159.1986.tb02858.x","article-title":"Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system","volume":"47","author":"Atack","year":"1986","journal-title":"J Neurochem."},{"key":"2022060616200899000_63.Supplement_1.33S.102","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-007-0083-6"},{"key":"2022060616200899000_63.Supplement_1.33S.103","doi-asserted-by":"crossref","unstructured":"Shinotoh H Hirano S Shimada H . PET imaging of acetylcholinesterase. In: Dierckx RA Otte A de Vries EF van Waarde A Lammertsma AA , eds. PET and SPECT of Neurobiological Systems. Springer International Publishing; 2020:193\u2013220.","DOI":"10.1007\/978-3-030-53176-8_7"},{"key":"2022060616200899000_63.Supplement_1.33S.104","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(92)90543-I"},{"key":"2022060616200899000_63.Supplement_1.33S.105","doi-asserted-by":"publisher","DOI":"10.1016\/0969-8051(94)90159-7"},{"key":"2022060616200899000_63.Supplement_1.33S.106","first-page":"649","article-title":"Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer\u2019s disease","volume":"37","author":"Irie","year":"1996","journal-title":"J Nucl Med."},{"key":"2022060616200899000_63.Supplement_1.33S.107","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(05)70293-2","article-title":"Preserved acetylcholinesterase activity in aged cerebral cortex","volume":"351","author":"Namba","year":"1998","journal-title":"Lancet."},{"key":"2022060616200899000_63.Supplement_1.33S.108","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.4.691"},{"key":"2022060616200899000_63.Supplement_1.33S.109","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/bs.irn.2018.07.027","article-title":"Molecular imaging of the cholinergic system in Parkinson\u2019s disease","volume":"141","author":"Bohnen","year":"2018","journal-title":"Int Rev Neurobiol."},{"key":"2022060616200899000_63.Supplement_1.33S.110","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/mdc3.13319","article-title":"The cholinergic brain in Parkinson\u2019s disease","volume":"8","author":"Pasquini","year":"2021","journal-title":"Mov Disord Clin Pract (Hoboken)."},{"key":"2022060616200899000_63.Supplement_1.33S.111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09124-6"},{"key":"2022060616200899000_63.Supplement_1.33S.112","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200008)48:2<194::AID-ANA9>3.0.CO;2-X"},{"key":"2022060616200899000_63.Supplement_1.33S.113","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.1.113"},{"key":"2022060616200899000_63.Supplement_1.33S.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2005.01.031"},{"key":"2022060616200899000_63.Supplement_1.33S.115","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H"},{"key":"2022060616200899000_63.Supplement_1.33S.116","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx356"},{"key":"2022060616200899000_63.Supplement_1.33S.117","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1a55"},{"key":"2022060616200899000_63.Supplement_1.33S.118","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.12.1745"},{"key":"2022060616200899000_63.Supplement_1.33S.119","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0971-0"},{"key":"2022060616200899000_63.Supplement_1.33S.120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(18)30032-2","article-title":"The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson\u2019s disease: a cross-sectional PET study","volume":"17","author":"Liu","year":"2018","journal-title":"Lancet Neurol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.263198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T19:21:56Z","timestamp":1654543316000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.263198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":120,"journal-issue":{"issue":"Supplement 1","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2967\/jnumed.121.263198"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.263198","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}